Showing 3221-3230 of 3543 results for "".
- Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002https://practicaldermatology.com/news/revance-launches-phase-2-belmont-study/2459035/Specialty biopharmaceutical company Revance Therapeutics, Inc. has initiated the BELMONT trial, a Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and
- FDA Approves Galderma's Soolantra to Treat Rosaceahttps://practicaldermatology.com/news/fda-approves-galdermas-soolantra-for-rosacea/2459038/The FDA approved Galderma’s Soolantra (ivermectin) Cream 1% for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. R Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are norma
- Chromogenex Releases Regenlite Transformhttps://practicaldermatology.com/news/chromogenex-releases-regenlite-transform/2459042/The latest addition to the Chromogenex family, Regenlite Transform is now available. It is specifically designed for managing inflammatory skin conditions without any discomfort, downtime or residual cell necrosis, the company says. A pure 585nm laser offers 300% more absorption in Oxyhae
- Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Studyhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-to-meet-with-fda-on-operational-aspects-of-pv-10-phase-3-melanoma-study/2459043/Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be me
- L'oreal USA Announces Changes In Leadership Within Active Cosmetics Divisionhttps://practicaldermatology.com/news/loreal-usa-announces-changes-in-leadership-within-active-cosmetics-division/2459045/Marc Toulemonde was appointed President of the Active Cosmetics Division of L’Oreal USA. In this role, Mr. Toulemonde will work on the SkinCeuticals, La Roche-Posay, Dermablend, and Vichy brands in the United States. Mr. Toulemonde brings expertise to the role from his m
- Cosmetic Surgery Forum 2014 Kicks Off in Las Vegashttps://practicaldermatology.com/news/cosmetic-surgery-forum-2014-kicks-off-in-las-vegas/2459046/Sessions for the sixth annual Cosmetic Surgery Forum are now underway at the Palazzo Resort and Casino in Las Vegas, with live injection sessions and panel discussions. In addition to expert perspectives on the latest innovations in aesthetic
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Valeant Comments On Allergan Announcementhttps://practicaldermatology.com/news/20141117-valeant_comments_on_allergan_announcement/2459060/Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the annou
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a